compound 39 (Davis et al., 2010)

Compound 39 is a small molecule Rho-associated kinase (ROCK) inhibitor characterized by a benzothiophene scaffold. It was identified through an ultra high-throughput enzymatic activity screen and optimized via structure-activity relationship (SAR) studies at the 2- and 5-positions of the benzothiophene scaffold. The compound targets both ROCK1 and ROCK2 isoforms. In preclinical research, specifically a monkey model of glaucoma-associated ocular hypertension, Compound 39 demonstrated the ability to substantially reduce intraocular pressure. Its mechanism of action involves increasing aqueous humor outflow through the trabecular meshwork, making it a potential therapeutic candidate for the treatment of glaucoma.

Other names

Benzothiophene-based ROCK inhibitor 39Benzothiophene-based ROCK inhibitor 39-Rho-associated kinase-Small molecule-Glaucoma